Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opening Session Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Nov
13
Today In Oncology
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
FDA Approves Ziftomenib for NMP1-Positive AML
Ezabenlimab, Induction Chemotherapy, and Adaptive Chemoradiotherapy in Stage III Squamous Cell Anal Carcinoma
Transfusion Access Prioritized Over Routine Hospice Services Among Patients With Blood Cancers
Advanced Epithelial Ovarian Cancer First-Line PARP Inhibitor Maintenance Therapy and Survival
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo